Please login to the form below

Not currently logged in
Email:
Password:

Lilly's Zyprexa on 'deadly drugs' list

A study has found that Zyprexa has one of the highest rates of suspect drug deaths, ranking thirteenth on the list of drugs with the most reported deaths and adverse events

A study conducted by the Institute for Safe Medication Practices and the Division of Public Health Sciences at Wake Forest University School of Medicine has found that Zyprexa has one of the highest rates of suspect drug deaths, ranking thirteenth on the list of drugs with the most reported deaths and adverse events.

Over the eight years of the study, Zyprexa was linked to 1,005 deaths and 4,110 adverse events. The information was posted on the FDA's Adverse Event Reporting System and was published in the Archives of Internal Medicine in September.

An atypical antipsychotic, Zyprexa is approved to treat schizophrenia and bipolar disorder. Literature about the drug for medical professionals notes that suicide attempts are "inherent to schizophrenia and bipolar disorder", however.

Zyprexa posted FY06 sales of USD 4.4bn and is Lilly's best-selling product. It has, however, also caused huge legal problems. Lilly has paid more than USD 1bn to settle tens of thousands of patient lawsuits claiming the company failed to disclose that Zyprexa causes weight gain, diabetes complications and other health problems.

Several states are suing Lilly, claiming it marketed Zyprexa for off-label uses, including treatment of adolescents, dementia, depression and autism, without warning about its risks.

Since Zyprexa was launched in 1996, it has been prescribed to about 20 million people around the world. The drug loses patent protection in 2011.

In late September 2007, a three-member FDA team initially urged rejecting the drug for paediatric use because of inconsistent data from studies in US and Russian teens.

In a 29 April 2007 memo posted on the FDA's website, Thomas Laughren, head of the agency's psychiatry division, said the drug's benefits in some studies outweighed the reviewers' concerns.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE The bold digital clock featured on the EUGDPR (EU General Data Protection Regulation)1 website indicates – to the second...
Health knowledge: Why is it so important?
Health knowledge plays an important role in population health, but by itself is rarely enough to prompt a change in the behaviours that cause the risks....
Personas: a top tool for personalising pharma marketing campaigns
Healthcare customers are calling for greater personalisation in care from providers. Here, we explain why personas are the top tool for ensuring your brand meets this need efficiently and effectively....

Infographics